Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01683773 | Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A | PHASE1 | COMPLETED | 40 | — | — | Sep 1, 2012 | Aug 1, 2014 | Sep 17, 2014 | 2 | United Kingdom |
To evaluate the safety profile of multiple doses of AERAS-402 alone, compared to one and two doses of AERAS-402 followed by MVA85A in healthy, BCG vaccinated adults, measured by number and severity of local and systemic adverse events
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Two doses of AERAS-402 (1x10\^11 vp intramuscular injection) followed by one dose of MVA85A (1x10\^8 pfu intradermal injection) |
| Group B | EXPERIMENTAL | One dose of AERAS-402 (1x10\^11 vp intramuscular injection) followed by one dose of MVA85A (1x10\^8 pfu intradermal injection) |
| Group C | EXPERIMENTAL | Three doses of AERAS-402 (1x10\^11 vp intramuscular injection) |
| Name | Type | Description |
|---|---|---|
| AERAS-402 | BIOLOGICAL | Intramuscular needle injection 1x10\^11 vp |
| MVA85A | BIOLOGICAL | Intradermal needle injection 1x10\^8 pfu |
Inclusion Criteria: Subjects must meet all of the following criteria to enter the trial: * Healthy adult aged 18-55 years * Resident in or near Oxford (for CCVTM) or Birmingham (for WTCRF; and able to travel to Oxford for vaccinations) for the duration of the trial period * No relevant findings in...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Viatris, Inc. | VTRS | 1 | PHASE3 | Bedaquiline |
| Johnson & Johnson | JNJ | 1 | PHASE2 | Bedaquiline, Background Regimen |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT164a1, BNT164b1 |
| Harvard Bioscience, Inc. | HBIO | 1 | — | Bdq, Lzd, Lfx, Dlm, Cfz |